Chester County News and Community Website
WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it will present at three investor conferences in March, with live webcasts available on its investor relations website.
Incyte to Present at Three March Investor Conferences Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported fourth-quarter and full-year 2025 financial results on February 10, posting revenue growth of 28% in the quarter and 21% for the year, and …
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) announced it will release its fourth-quarter and full-year 2025 financial results before the market opens on Tuesday, February 10, followed by a conference call …
Incyte Sets February 10 Call to Unveil Q4 and Full-Year 2025 Results Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) on Thursday unveiled breakthrough results from a pivotal late-stage cancer trial that could redefine first-line treatment for one of the most aggressive forms of …
New Incyte Drug Combo Shows Power Against Deadly Lymphoma Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, placing the biopharmaceutical company in front of …
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, introducing …
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said Hervé Hoppenot recently resigned from its board of directors, effective immediately, formally ending a transition period that followed his long tenure as the …
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported strong early-stage clinical results for an experimental precision antibody that sharply reduced disease markers in patients with essential thrombocythemia, bolstering hopes for a …
Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer Read More WILMINGTON, DE — Incyte Corporation (INCY) is using a sizable equity-based compensation package to secure its new top legal executive, underscoring the company’s emphasis on long-term performance and shareholder alignment …
Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance Read More WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) appointed Richard Hoffman as executive vice president and general counsel, effective December 1, adding a seasoned life sciences attorney to its top ranks …
Incyte Names Veteran Biopharma Attorney as New General Counsel Read More